As erlotinib is the only FDA-approved clinical EGFR-targeted inhibitor for the treatment of advanced lung cancer in the United States, we further investigated its potential use in combination with MET inhibition against erlotinib-resistant H1975 cells using an in vitro cellular viability assay and BLI tumour xenograft growth assay in vivo. Here, EGFR is linked to lung cancer.